Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs
Journal of Oncology Pharmacy Practice · 2025
DOI: 10.1177/10781552241279019 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Vitalis Okwor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Clinical Oncology, University of Nigeria Teaching Hospital, Enugu, Nigeria. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Postmenopause, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
Objective we aim to synthesize available evidence on the effectiveness of hormonal plus targeted therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer. Data Sources and Methods We searched the following databases: Medline , PubMed, Cochrane Library, CINAHL, Web of Science, Scopus, and African Journal. Only studies that investigated the effectiveness of hormonal therapy combined with targeted therapy for HR+/HER2- advanced breast cancer treatment were included. The outcomes were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). A random-effect meta-analysis model was employed. Statistical analysis was performed using Comprehensive Meta-analysis version 3.
Results
24 studies were included in the meta-analysis with an overall sample size of 7635. Median PFS, OS and ORR were found to be significantly increased in the combination group compared to hormonal monotherapy [SMD = 6.072 (95% CI = 3.785–8.360), p < 0.001], [SMD = 1.614 (95% CI = 0.139–3.089), p = 0.032] and [OR = 1.584 (CI 1.134–2.213), p = 0.007] respectively. Subgroup analysis showed a significant difference in PFS and ORR between patients who received “hormonal therapy + CDK4/6 inhibitors” vs hormonal therapy only [SMD = 6.015 (CI 3.069–8.960), p < 0.001], (OR = 1.828 (CI 1.030–3.243), p = 0.039] respectively.
Conclusion
Compared with hormonal monotherapy, targeted plus hormonal therapy significantly improves PFS, OS and ORR in postmenopausal women with HR+/HER2- advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Clinical Oncology, University of Nigeria Teaching Hospital, Enugu, Nigeria.
- Department of Chemical Pathology, College of Medicine, University of Nigeria Ituku-Ozalla Campus, Enugu, Nigeria.
- Department of Physiotherapy, University of Nigeria Teaching Hospital, Enugu, Enugu.
- Department of Physiotherapy, Evangel University Akaeze, Enugu, Nigeria.
ORCID-Profile: Maryjane Ukwuoma, Martins Nweke
Zitieren
APA
Okwor, V., Okwor, C. J., Ukwuoma, M., & Nweke, M. (2025). Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241279019
Vancouver
Okwor V, Okwor CJ, Ukwuoma M, Nweke M. Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs. Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241279019
BibTeX
@article{Okwor2025,
author = {Okwor, Vitalis and Okwor, Chika Juliet and Ukwuoma, Maryjane and Nweke, Martins},
title = {Effectiveness of combined targeted and hormonal therapies for post-menopausal women with hormone receptor-positive and HER2-negative advanced breast cancer: A systematic review and meta-analysis of RCTs},
journal = {Journal of Oncology Pharmacy Practice},
year = {2025},
doi = {10.1177/10781552241279019}
}
EUVIMED